Overview of the Evidence Base
Treatment-resistant depression (TRD) affects approximately 30% of patients with major depressive disorder (MDD), representing a significant unmet clinical need. Over the past two decades, low-dose ketamine --- typically administered as a single intravenous infusion at 0.5 mg/kg over 40 minutes --- has emerged as one of the most studied novel interventions for TRD. The accumulation of randomized controlled trials (RCTs) has enabled multiple meta-analyses that offer a high-level view of ketamine's antidepressant efficacy.
Key Meta-Analytic Findings
Zarate and Colleagues: Early Signal Detection
The foundational work from the NIMH by Zarate et al. (2006), a landmark crossover RCT in Biological Psychiatry, demonstrated rapid antidepressant effects within hours of a single infusion. For a complete overview of how ketamine works, see the educational resource. While not a meta-analysis itself, this trial catalyzed subsequent research that would later be pooled across analytic reviews.
Caddy et al. (2015) --- Cochrane Review
The Cochrane Database of Systematic Reviews published an early systematic review by Caddy et al. examining ketamine and other glutamate receptor modulators for depression. This review identified a limited but consistent signal favoring ketamine over placebo at 24 hours and up to 7 days post-infusion. The authors noted that the evidence base at that time was constrained by small sample sizes and short follow-up periods, but the direction of effect was unambiguous.
Kishimoto et al. (2016) --- Pooled Efficacy Analysis
Kishimoto and colleagues conducted a meta-analysis published in Psychological Medicine that pooled data from nine RCTs. They reported a large effect size (Cohen's d approximately 0.9) for ketamine versus placebo at 24 hours post-infusion. Response rates (defined as a 50% or greater reduction in depression severity scores) were significantly higher in ketamine groups, with a number needed to treat (NNT) of approximately 3 to 5 across studies. Remission rates were also significantly elevated, though less robust than response rates.
Fond et al. (2014) and Coyle and Laws (2015)
Multiple independent teams converged on similar conclusions. Fond et al. reported in Journal of Psychiatric Research that ketamine demonstrated significant antidepressant effects at 24 hours, 72 hours, and 7 days post-infusion compared with saline or midazolam controls. Coyle and Laws, publishing in Human Psychopharmacology, confirmed these findings while highlighting the importance of active placebo controls (such as midazolam) to account for the subjective dissociative effects of ketamine that could compromise blinding.
Zheng et al. (2018) --- Repeated Infusion Protocols
As clinical practice evolved toward repeated infusion protocols, Zheng et al. published a meta-analysis in Journal of Affective Disorders examining serial ketamine infusions. Their findings indicated that repeated doses (typically two to three infusions per week over two to three weeks) produced a more sustained antidepressant effect compared to single infusions. Response rates with repeated dosing reached 70% in some pooled estimates, with remission rates approaching 30% to 40%.
Effect Size Characterization
Across the major meta-analyses, several consistent patterns emerge:
- Acute efficacy (24 hours): Large effect sizes (Hedges' g or Cohen's d ranging from 0.8 to 1.2) favoring ketamine over placebo.
- Short-term efficacy (3--7 days): Moderate-to-large effect sizes persisting through the first week.
- Durability beyond 7 days: Effect sizes attenuate considerably, with most patients experiencing symptom recurrence within 1 to 2 weeks of a single infusion.
- Repeated infusion protocols: Demonstrated improved durability, though long-term data beyond 4 to 6 weeks remain limited.
Methodological Considerations
Blinding Challenges
A recurring concern in ketamine meta-analyses is the integrity of blinding. Ketamine produces perceptible dissociative and psychotomimetic effects that may allow patients and raters to distinguish active treatment from placebo. Studies using midazolam as an active control have attempted to mitigate this, and meta-analytic subgroup analyses generally show that ketamine's advantage persists even against active placebos, though effect sizes may be modestly reduced.
Publication Bias
Funnel plot analyses in several meta-analyses have raised concerns about potential publication bias, though formal statistical tests (e.g., Egger's test) have yielded mixed results. The relatively small number of studies in earlier meta-analyses limits the power of these assessments.
Heterogeneity in Study Design
Variability in infusion protocols, outcome measures (MADRS vs. HDRS vs. BDI), timing of assessments, and patient populations contributes to statistical heterogeneity. Sensitivity analyses excluding outlier studies have generally preserved the significance and direction of the pooled effect.
Clinical Implications
The meta-analytic evidence confirms that low-dose intravenous ketamine produces rapid and clinically meaningful antidepressant effects in TRD, with NNT values comparable to or better than many established strategies. The transient nature of response after single infusions underscores the need for repeated dosing protocols or maintenance strategies.
Future Directions
Ongoing and future meta-analyses will benefit from the expanding trial base, including studies of intranasal esketamine (the S-enantiomer, FDA-approved as Spravato), oral ketamine formulations, and direct comparisons between racemic ketamine and esketamine. Individual patient data meta-analyses represent a particularly valuable next step, as they may identify moderators of treatment response and inform personalized treatment approaches.
References
- PubMed: Systematic Review and Meta-Analysis of Ketamine in the Rapid Treatment of Major Depressive Episodes — Foundational meta-analysis of RCTs examining ketamine's rapid antidepressant efficacy
- PubMed: Real-World Effectiveness of Ketamine in Treatment-Resistant Depression — Systematic review and meta-analysis of ketamine effectiveness in real-world clinical settings
- NIMH: Depression Overview — National Institute of Mental Health information on depression and treatment-resistant depression
- MedlinePlus: Esketamine Nasal Spray Drug Information — National Library of Medicine information on FDA-approved esketamine nasal spray for treatment-resistant depression
- WHO: Depression Fact Sheet — World Health Organization global overview of depressive disorders and treatment approaches
Share